
Matthew MY Lee
@matthewmylee
Cardiology Clinical Senior Lecturer @UoGHeartFailure BHF SCMH University of Glasgow
ID: 47779629
16-06-2009 23:48:11
103 Tweet
226 Followers
269 Following

Ready for #aficamten, a next-in-class myosin inhibitor for oHCM? See the results: bit.ly/3Byamm0 #JACC #cvHCM #SEQUOIA Martin Maron, MD @JJheart_doc Matthew MY Lee



Excited to share our latest study showing kidney, CV and survival benefits of GLP-1 receptor agonists just published in The Lancet Diabetes & Endocrinology Time-limited free access authors.elsevier.com/a/1k9u77tNucqx… 1/


EMPRESS-MI: Empagliflozin vs placebo, n=105 w/ LVSD (mean LVEF 34.8%) post-AMI (24wks): ↔️LVESVI, LVEDVI, LVEF, LAVI, LVMI ↔️NT-proBNP, hs-TnI ↗️Hct ↘️urate, weight 🔗 doi.org/10.1002/ejhf.3… Jaclyn Carberry Kieran Docherty Mark Petrie Colin Berry University of Glasgow Heart Failure Research Group UofG SCMH


What’s new in #HF Dec 2024? doi.org/10.1002/ejhf.3… #GDMT in ESC HF III Registry #HFimpEF predictors LV vol & exe capacity in #HFpEF HFpEF in repaired #Coarctation Aorta #CMR #DCMmrEF risk stratificatn #Chagas cardiomyopathy Pau Codina Verdaguer @DaniTomasoni Alberto Aimo European Society of Cardiology Journals


🗞️ SUGAR-DM-HF #CMR estimated PCWP & congestion markers, and effect of #empagliflozin in #HFrEF with dysglycaemia European Society of Cardiology Journals Giuseppe Galati Amr Abdin Henry Han HFAPresident bit.ly/3C55VQt


The 2024 top 10 papers in heart failure!!! doi.org/10.1093/eurhea… #cardiotwitter, European Society of Cardiology Journals, European Society of Cardiology


⚖️Direct tissue vs wt loss effects—both matter, but how much?🤔 💉#GLP1RA in #Obesity & chronic conditions: 🩸#T2DM📈#HTN🏥#MACE❤️#HFpEF 🫘#CKD⚠️#MASH💤#OSA🦴#OA 🔗 doi.org/10.1016/S2213-… Grateful to Naveed Sattar🙏 #CardioTwitter The Lancet Diabetes & Endocrinology Metabolic Medicine UofG SCMH UofG MVLS



Cardiovascular, Kidney & Mortality Outcomes With Injectable & Oral GLP1-RA in T2 Diabetes An updated meta-analysis of >70,000 patients after the SOUL trial by Matthew MY Lee et al. ⬇️ 14% MACE ⬇️ 14% heart failure ⬇️ 17% CKD ⬇️ 12% all-cause mortality diabetesjournals.org/care/article/d…


New in CJASN 📢 Our meta-analysis of 66 CKD trials shows both acute & chronic GFR slope independently predict clinical outcomes Findings support 3-year total slope as the optimal surrogate endpoint for CKD trials ASN Publications: doi.org/10.2215/CJN.00…


What's new in heart failure? April 2025 onlinelibrary.wiley.com/doi/full/10.10… #EJHF European Society of Cardiology Journals EJHF Editor-in-Chief


What’s new in #HF June 2025? 🔗 doi.org/10.1002/ejhf.3… 💧 Natriuresis & congestion 📡 Remote PAP monitoring 💔 Acute & advanced HF 🧬 Cardio-oncology 🔍 HFmrEF/HFpEF 🩸 IV iron Pau Codina Verdaguer @DaniTomasoni Alberto Aimo European Society of Cardiology Journals




Pleased to share our review on heart failure and obesity published in Nature Reviews Cardiology Nature Reviews Cardiology 🔗 doi.org/10.1038/s41569… 🔗 rdcu.be/eyuxe Very grateful to my amazing co-authors Laura Meems DirkvanVeldhuisen NaveedSattar #HeartFailure #HFpEF #Obesity
